The average one-year price target for 10x Genomics (BMV:TXG) has been revised to MX$958.28 per share. This represents an increase of 12.04% from the prior estimate of MX$855.29 dated September 13, ...
The average one-year price target for 10x Genomics (NASDAQGS:TXG) (LSE:0A88) has been revised to $60.62 / share. This is an increase of 13.66% from the prior estimate of $53.33 dated September 11, ...
TXG begins Atera shipments as orders top 40 systems, highlighting strong early demand and broad research interest in its ...
PRNewswire/ -- (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, ...
For decades, cancer treatment has largely followed a one-size-fits-all approach: the same chemotherapy regimen given to every ...
Veracyte has acquired Convergent Genomics in a transaction valued at up to $180 million, adding the UroAmp urinary tumor DNA ...
Researchers at Baylor College of Medicine, the Duncan Neurological Research Institute (Duncan NRI) at Texas Children's ...
Genomics, AI and precision diagnostics are advancing targeted therapies, improving outcomes and reducing treatment waste across oncology, cardiology and rare diseasesDublin, Sept. 30, 2026 (GLOBE ...
Origin Genomics aims to prove the potential benefits of its technology for editing disease-causing genes in human embryos ...
Cancer genomics is the study of the totality of DNA sequence and gene expression differences between tumour cells and normal host cells. It aims to understand the genetic basis of tumour cell ...
Introduced in April of this year, Atera brings together whole transcriptome analysis, sub-cellular resolution, single cell ...
Shaun Mahony, professor of biochemistry and molecular biology in the Penn State Eberly College of Science, has been named the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results